Vietnam jails former politburo official for 13 years in graft crackdown

HANOI (Reuters) – A court in Vietnam on Monday sentenced a former politburo official to 13 years in prison and another high-profile energy official to life imprisonment for embezzlement and violating state rules, in a corruption crackdown, state media said.

UK’s Computacenter says to beat 2017 expectations, sees stable 2018

(Reuters) – Computacenter Plc’s 2017 adjusted pre-tax results are set to beat expectations driven by strength across Germany, the United Kingdom and France, the British IT services company said on Monday.

Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases.

Bangladesh says start of Rohingya return to Myanmar delayed

PALONGKHALI, Bangladesh (Reuters) – Bangladesh has delayed the repatriation of Rohingya Muslim refugees to Myanmar, set to start on Tuesday, because the process of compiling and verifying the list of people to be sent back is incomplete, a senior Bangladesh official said.

Exclusive: U.S. sanctions curb Microsoft sales to hundreds of Russian firms

MOSCOW (Reuters) – Two of Microsoft’s official distributors in Russia have imposed restrictions on sales of Microsoft software to more than 200 Russian companies following new U.S. sanctions, according to notifications circulated by the distributors.

Simona Halep beats Naomi Osaka to reach Australian Open quarter-finals

World number one Simona Halep beats Japan’s Naomi Osaka in straight sets to reach the Australian Open quarter-finals.

Australian Open: Roger Federer beats Marton Fucsovics in straight sets

Roger Federer eases through to Australian Open quarter-finals with a straight-set win over Marton Fucsovics.

Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases.